Sun, Yanxiu
Hammer, Maximilian
Yildirim, Timur M.
Khoramnia, Ramin
Auffarth, Gerd U.
Funding for this research was provided by:
Klaus-Tschira-Stiftung
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 2 July 2021
Accepted: 12 October 2021
First Online: 2 November 2021
Competing interests
: Y.Sun and M. Hammer have nothing to disclose. T. Yildirim reports non-financial support from Alcon. R. Khoramnia reports grants, personal fees and non-financial support from Alimera, Alcon, Bayer, Johnson&Johnson, Hoya, Novartis, Physiol, Rayner and Roche, grants from Chengdu Kanghong, personal fees and non-financial support from Allergan, Kowa, Oculentis/Teleon, Oculus, Santen, and Acufocus. G. Auffarth reports grants, personal fees, non-financial support and consulting fees from Johnson&Johnson and Alcon, grants, personal fees and non-financial support from Carl Zeiss Meditec, Hoya, Kowa, Oculentis/Teleon, Rayner, Santen, Sifi, Ursapharm, grants and personal fees from Biotech, Oculus, EyeYon, grants from Acufocus, Anew, Contamac, Glaukos, Physiol, Rheacell. All stated conflicts of interest are outside the submitted work.